Ginkgo Bioworks Holdings, Inc.
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
DNA$12.01-2.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share data)
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Cell Engineering revenue (1) | $39,134 | $36,205 | $77,364 | $64,094 |
| Biosecurity revenue | 10,470 | 20,001 | 20,558 | 30,056 |
| Total revenue | 49,604 | 56,206 | 97,922 | 94,150 |
| Costs and operating expenses: | ||||
| Cost of Biosecurity revenue | 9,442 | 11,807 | 17,399 | 21,009 |
| Cost of other revenue | 5,380 | 1,914 | 9,470 | 1,914 |
| Research and development | 53,370 | 134,221 | 124,293 | 270,678 |
| General and administrative | 43,279 | 66,285 | 92,322 | 136,572 |
| Goodwill impairment | — | 47,858 | — | 47,858 |
| Restructuring charges | 3,674 | 17,066 | 8,947 | 17,066 |
| Total operating expenses | 115,145 | 279,151 | 252,431 | 495,097 |
| Loss from operations | (65,541) | (222,945) | (154,509) | (400,947) |
| Other income (expense): | ||||
| Interest income, net | 6,083 | 10,313 | 12,164 | 22,024 |
| Loss on investments | (229) | (6,826) | (3,922) | (9,370) |
| Change in fair value of warrant liabilities | — | 3,233 | — | 4,173 |
| Other income (expense), net | (896) | (766) | (5,185) | 1,249 |
| Total other income | 4,958 | 5,954 | 3,057 | 18,076 |
| Loss before income taxes | (60,583) | (216,991) | (151,452) | (382,871) |
| Income tax (benefit) expense | (283) | 190 | (195) | 221 |
| Net loss | $(60,300) | $(217,181) | $(151,257) | $(383,092) |
| Net loss per share: | ||||
| Basic | $(1.10) | $(4.23) | $(2.77) | $(7.55) |
| Diluted | $(1.10) | $(4.23) | $(2.77) | $(7.56) |
| Weighted average common shares outstanding: | ||||
| Basic | 54,858,982 | 51,370,029 | 54,552,006 | 50,740,744 |
| Diluted | 54,858,982 | 51,375,599 | 54,552,006 | 50,746,314 |
| Comprehensive loss: | ||||
| Net loss | $(60,300) | $(217,181) | $(151,257) | $(383,092) |
| Other comprehensive (loss) income: | ||||
| Foreign currency translation adjustment | 2,586 | (172) | 3,435 | (3,207) |
| Unrealized gains (loss) on available-for-sale securities | (83) | — | 24 | — |
| Total other comprehensive (loss) income | 2,503 | (172) | 3,459 | (3,207) |
| Comprehensive loss | $(57,797) | $(217,353) | $(147,798) | $(386,299) |
(1)Includes related party revenue of $420 and $5,146 for the three months ended June 30, 2025 and 2024, respectively, and $8,518 and $5,819 for the six months ended June 30, 2025 and 2024, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.